Cramer’s lightning round: I like Procter & Gamble over Walmart

Cramer’s lightning round: I like Procter & Gamble over Walmart


Iron Mountain Inc: “Right now I don’t want to back away from it. … We may have to do new work on Iron Mountain to see if it’s as safe as we think it is.”

McKesson Corp: “[Buy.]”

Disclaimer: Cramer’s Charitable Trust owns shares of Procter & Gamble and Johnosn & Johnson.

Cramer's lightning round: I like Procter & Gamble over Walmart

Jim Cramer’s Guide to Investing

Click here to download Jim Cramer’s Guide to Investing at no cost to help you build long-term wealth and invest smarter.



Source

Stellantis stock off 43% as Jeep maker turns five, executes turnaround
Business

Stellantis stock off 43% as Jeep maker turns five, executes turnaround

Stellantis North America COO and Jeep CEO Antonio Filosa speaks during the Stellantis press conference at the Automobility LA 2024 car show at Los Angeles Convention Center in Los Angeles, California, November 21, 2024. Etienne Laurent | AFP | Getty Images DETROIT — Five years after the transatlantic automaker Stellantis was formed through a merger, […]

Read More
Disney dominated the 2025 box office. Here’s how it could keep the crown in 2026
Business

Disney dominated the 2025 box office. Here’s how it could keep the crown in 2026

Courtesy of Disney Enterprises Inc. Blue aliens, a family of superheroes and a city of talking animals boosted the Walt Disney Company to the top of the domestic box office in 2025. Full-year ticket sales in the United States and Canada rose about 4% from 2024 to $9.05 billion. Disney accounted for the highest share […]

Read More
Novo Nordisk shares rise 5% after Wegovy obesity pill has ‘solid’ launch
Business

Novo Nordisk shares rise 5% after Wegovy obesity pill has ‘solid’ launch

A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, US, on Thursday, Jan. 15, 2026. George Frey | Bloomberg | Getty Images Shares of Novo Nordisk rose more than 5% on Friday after early prescription data showed an encouraging start to the U.S. launch of the company’s new GLP-1 pill […]

Read More